Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sotorasib + platinum doublet chemotherapy
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Lumakras (sotorasib) in combination with platinum doublet chemotherapy is an investigational combination regimen being evaluated for the treatment of KRAS G12C-mutated advanced or metastatic non-small cell lung cancer (NSCLC). Sotorasib is a small molecule that specifically and irreversibly inhibits the KRAS G12C mutant protein by locking it in an inactive GDP-bound state. Platinum doublet chemotherapy typically consists of a platinum agent (such as carboplatin or cisplatin) combined with a doublet partner (such as pemetrexed), which works by damaging DNA and inhibiting cell division. This combination regimen is designed to enhance anti-tumor efficacy and delay or overcome the emergence of resistance pathways in KRAS G12C-mutated NSCLC. It is currently being evaluated in clinical trials, including the Phase 3 CodeBreaK 202 study as a first-line therapy for patients with PD-L1-negative, advanced KRAS G12C-mutated NSCLC.
- Other names
- Lumakras + platinum doublet chemotherapyLumakras + platinum-based chemotherapyLumakras + platinum-doublet chemotherapysotorasib + carboplatin + pemetrexedsotorasib + cisplatin + pemetrexedsotorasib + platinum doublet chemotherapysotorasib + platinum-based chemotherapysotorasib + platinum-doublet chemotherapy
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)TS (Thymidylate synthase)
Beyond the preview
Go deeper on sotorasib + platinum doublet chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sotorasib + platinum doublet chemotherapy.